Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | OSBP | P22059 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 13/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466045 | 1.00 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL28057984 | 1.00 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4961477 | 0.90 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL5935410 | 0.90 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL103515 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL932623 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2185461 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL720338 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18529717 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10943687 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105879107-A | Antimycotic polymerisable bone cement and a method for the production thereof | 贺利氏医疗有限责任公司 | 2016-08-24 | — | — | CN | claimed |
| US-4839175-A | USING CHOLESTEROL DERIVATIVES; FOR OPTHALMIC DRUG DELIVERY | LIPOSOME TECHNOLOGY, INC. (US) | 1989-06-13 | — | — | US | claimed |
| EP-0316345-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1989-05-24 | — | — | EP | claimed |
| EP-0316345-A4 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE. | LIPOSOME TECHNOLOGY INC (US) | 1989-05-16 | — | — | EP | claimed |
| US-4804539-A | Ophthalmic liposomes | LIPOSOME TECHNOLOGY, INC. (US) | 1989-02-14 | — | — | US | claimed |
| WO-1988000824-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1988-02-11 | — | — | WO | claimed |
| US-4496482-A | FROM ISOCYANATOSILANES, FOR BONDING TO SUBSTRATES | UNION CARBIDE CORPORATION (US) | 1985-01-29 | — | — | US | claimed |
| CN-111698991-A | Inhibitors of protease activated receptor-2 | 武田药品工业株式会社 | 2020-09-22 | — | — | CN | disclosed |
| US-9931430-B2 | Antimycotic polymerisable bone cement and a method for the production thereof | HERAEUS MEDICAL GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| CN-105879107-A | Antimycotic polymerisable bone cement and a method for the production thereof | 贺利氏医疗有限责任公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20160235883-A1 | Antimycotic Polymerisable Bone Cement and a Method for the Production Thereof | HERAEUS MEDICAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20140004499-A1 | BIOSURFACE ENGINEERING | BOVIN NICOLAI VLADIMIROVICH (RU) | 2014-01-02 | — | — | US | disclosed |
| WO-2012099477-A1 | BIOSURFACE ENGINEERING | BOVIN NICOLAI VLADIMIROVICH (RU) | 2012-07-26 | — | — | WO | disclosed |
| US-4839175-A | USING CHOLESTEROL DERIVATIVES; FOR OPTHALMIC DRUG DELIVERY | LIPOSOME TECHNOLOGY, INC. (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0316345-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| EP-0316345-A4 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE. | LIPOSOME TECHNOLOGY INC (US) | 1989-05-16 | — | — | EP | disclosed |
| US-4804539-A | Ophthalmic liposomes | LIPOSOME TECHNOLOGY, INC. (US) | 1989-02-14 | — | — | US | disclosed |
| WO-1988000824-A1 | LIPOSOMES WITH ENHANCED RETENTION ON MUCOSAL TISSUE | LIPOSOME TECHNOLOGY, INC. (US) | 1988-02-11 | — | — | WO | disclosed |
| US-4496482-A | FROM ISOCYANATOSILANES, FOR BONDING TO SUBSTRATES | UNION CARBIDE CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| US-4316041-A | BOND TO GLASS | UNION CARBIDE CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004499-A1 | BIOSURFACE ENGINEERING | SGMS1, SGMS2, LSS | USP2 3094/4885CYP46A1 244/4885LMNA 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.